Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Budesonide
Therapeutic Area : Immunology
Study Phase : Phase III
Recipient : Marinomed Biotech
Deal Size : $22.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Shandong Luoxin will gain the exclusive rights for the development, manufacture, and commercialization of Budesolv® (Budesonide Nasal spray) in China (including Chinese mainland, Hong Kong and Macao SAR, Taiwan region).
Brand Name : Budesolv
Molecule Type : Small molecule
Upfront Cash : $2.0 million
October 19, 2021
Lead Product(s) : Budesonide
Therapeutic Area : Immunology
Highest Development Status : Phase III
Recipient : Marinomed Biotech
Deal Size : $22.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
